New insights into the burden and costs of multiple sclerosis in Europe

Multiple Sclerosis Journal - Tập 23 Số 8 - Trang 1123-1136 - 2017
Gisela Kobelt1, Alan J. Thompson2, Jenny Berg3, Mia Gannedahl3, Jennifer Eriksson3
1European Health Economics, Mulhouse, France
2Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
3Mapi Group, Stockholm, Sweden

Tóm tắt

Background: The current focus in multiple sclerosis (MS) is on early diagnosis and drug intervention, with a view to modifying disease progression. Consequently, healthcare costs have shifted from inpatient care and rehabilitation to outpatient care. Objectives: This European burden of illness study provides data that can be combined with other evidence to assess whether management approaches provide value to society. Methods: A cross-sectional study was conducted in 16 countries. Patients reported on their disease, health-related quality of life (HRQoL) and resource consumption. Descriptive analyses were performed by disease severity. Costs are reported from a societal perspective in 2015€ PPP (adjusted for purchasing power parity). Results: The 16,808 participants had a mean age of 51.5 years, and 52% had relapsing–remitting multiple sclerosis (RRMS). Work capacity declined from 82% to 8%, and utility declined from normal population values to less than zero with advancing disease. Mean costs were 22,800€ PPP in mild, 37,100€ PPP in moderate and 57,500€ PPP in severe disease; healthcare accounted for 68%, 47% and 26%, respectively. Fatigue and cognitive difficulties were reported by 95% and 71% of participants, respectively; both had a significant independent effect on utility. Conclusion: Costs and utility were highly correlated with disease severity, but resource consumption was heavily influenced by healthcare systems organisation and availability of services.

Từ khóa


Tài liệu tham khảo

10.3109/00365529609094543

O’Brien B. Multiple sclerosis. London: Office of Health Economics, 1987, https://www.ohe.org/system/files/private/publications/162%20-%201987_Multiple_Sclerosis_OBrien.pdf?download=1 (accessed 5 October 2016).

Blumhardt L, 1996, Br J Med Econ, 10, 99

10.2165/00019053-199813050-00012

10.1007/s00415-012-6656-6

10.1016/j.msard.2016.07.003

10.1016/S1474-4422(14)70330-8

10.1136/jnnp.2006.090365

Kobelt G, Lindgren P, Parkin D, Costs and quality of life in multiple sclerosis: A cross-sectional observational study in the UK. EFI research report no. 398, 2000. Stockholm: Stockholm School of Economics, http://swopec.hhs.se/hastef/papers/hastef0398.pdf (accessed 5 October 2016).

10.1046/j.1468-1331.2001.00169.x

10.1007/s101980100057

Kobelt G, Kasteng F. Access to innovative treatments in multiple sclerosis in Europe. Brussels: The European Federation of Pharmaceutical Industry Associations (EFPIA), 2009, http://www.comparatorreports.se/Access%20to%20MS%20treatments%20-%20October%202009.pdf (accessed 5 October 2016).

Edling A, Stenberg AM. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). Stockholm: Pharmaceutical Benefits Board, 2003, http://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf (accessed 5 October 2016).

National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. National institute for Health and Care Excellence, 2013, https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781 (accessed 5 October 2016).

Radick L, 2015, Am Health Drug Benefits, 8, 448

10.1007/s40258-013-0034-0

10.1007/s40273-013-0063-4

10.1007/s40273-014-0150-1

Kobelt G., 2006, Int MS J, 13, 17

10.1016/j.jval.2012.11.002

10.1177/1352458514528760

10.1016/0168-8510(90)90421-9

Dolan P, Gudex C, Kind P, A social tariff for EuroQol: Results from a UK general population survey (discussion paper number 138). York: Centre for Health Economics, University of York, 1995, http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20138.pdf (accessed 5 October 2016).

Paris V, Belloni A. Value in pharmaceutical pricing. OECD Publishing, 2013, http://apps.who.int/medicinedocs/documents/s21368en/s21368en.pdf (accessed 5 October 2016).

10.1186/s13561-016-0109-3

10.1212/WNL.0000000000000560

Fox RJ, 2015, Neurodegener Dis Manag, 5, 3

10.1037/rep0000045

10.1080/13803395.2016.1164124

10.1097/WNN.0b013e31822a20ae

10.1177/1352458515616205

Thông tin
Thông tin xuất bản

Multiple Sclerosis Journal

Tập 23 Số 8

1123-1136

Thông tin tác giả